Overview

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Rosiglitazone